FY2027 Earnings Forecast for VRTX Issued By Erste Group Bank

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) – Stock analysts at Erste Group Bank raised their FY2027 EPS estimates for shares of Vertex Pharmaceuticals in a report issued on Tuesday, March 24th. Erste Group Bank analyst H. Engel now anticipates that the pharmaceutical company will post earnings per share of $19.48 for the year, up from their previous estimate of $19.31. The consensus estimate for Vertex Pharmaceuticals’ current full-year earnings is $15.63 per share.

A number of other research firms have also issued reports on VRTX. Citigroup increased their target price on Vertex Pharmaceuticals from $575.00 to $585.00 and gave the company a “buy” rating in a report on Tuesday, March 10th. Bank of America boosted their price target on Vertex Pharmaceuticals from $571.00 to $598.00 and gave the stock a “buy” rating in a report on Tuesday, March 10th. Stifel Nicolaus upped their price objective on Vertex Pharmaceuticals from $445.00 to $466.00 and gave the company a “hold” rating in a research report on Friday, February 13th. Wells Fargo & Company increased their price objective on Vertex Pharmaceuticals from $460.00 to $515.00 and gave the company an “overweight” rating in a research note on Wednesday, December 10th. Finally, Evercore lifted their price objective on Vertex Pharmaceuticals from $475.00 to $530.00 and gave the stock an “outperform” rating in a research report on Friday, January 23rd. One research analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and five have issued a Hold rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $554.30.

Vertex Pharmaceuticals Price Performance

Shares of VRTX opened at $433.07 on Thursday. Vertex Pharmaceuticals has a 1-year low of $362.50 and a 1-year high of $510.77. The stock has a market cap of $110.01 billion, a price-to-earnings ratio of 28.25, a price-to-earnings-growth ratio of 1.94 and a beta of 0.31. The firm has a 50 day simple moving average of $469.10 and a 200-day simple moving average of $441.91.

Vertex Pharmaceuticals (NASDAQ:VRTX) last announced its quarterly earnings results on Thursday, February 12th. The pharmaceutical company reported $5.03 earnings per share (EPS) for the quarter, missing the consensus estimate of $5.05 by ($0.02). The business had revenue of $3.19 billion during the quarter, compared to analysts’ expectations of $3.18 billion. Vertex Pharmaceuticals had a net margin of 32.94% and a return on equity of 24.30%. The firm’s revenue for the quarter was up 9.5% on a year-over-year basis. During the same period last year, the company earned $3.98 EPS.

Insider Transactions at Vertex Pharmaceuticals

In other Vertex Pharmaceuticals news, EVP Ourania Tatsis sold 260 shares of Vertex Pharmaceuticals stock in a transaction that occurred on Wednesday, February 25th. The shares were sold at an average price of $486.35, for a total value of $126,451.00. Following the completion of the sale, the executive vice president directly owned 46,763 shares of the company’s stock, valued at approximately $22,743,185.05. The trade was a 0.55% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Mark E. Bunnage sold 620 shares of the stock in a transaction on Wednesday, February 25th. The stock was sold at an average price of $486.35, for a total value of $301,537.00. Following the transaction, the executive vice president directly owned 7,284 shares in the company, valued at approximately $3,542,573.40. This represents a 7.84% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 93,485 shares of company stock worth $43,967,586 in the last three months. 0.20% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Vertex Pharmaceuticals

Several large investors have recently added to or reduced their stakes in VRTX. Mitsubishi UFJ Asset Management Co. Ltd. raised its stake in Vertex Pharmaceuticals by 3.8% during the third quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 544,978 shares of the pharmaceutical company’s stock valued at $213,435,000 after buying an additional 20,053 shares in the last quarter. Leuthold Group LLC acquired a new position in shares of Vertex Pharmaceuticals in the 3rd quarter worth approximately $5,030,000. Danske Bank A S acquired a new position in shares of Vertex Pharmaceuticals in the 3rd quarter worth approximately $64,417,000. Advisory Resource Group bought a new stake in shares of Vertex Pharmaceuticals in the 3rd quarter valued at approximately $1,286,000. Finally, Generali Asset Management SPA SGR raised its position in shares of Vertex Pharmaceuticals by 41.8% during the 3rd quarter. Generali Asset Management SPA SGR now owns 23,569 shares of the pharmaceutical company’s stock valued at $9,231,000 after acquiring an additional 6,942 shares in the last quarter. 90.96% of the stock is currently owned by hedge funds and other institutional investors.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Inc is a Boston-based biotechnology company focused on the discovery, development and commercialization of therapies for serious diseases. Founded in 1989, Vertex built its reputation on research-driven drug development and is best known for its work in cystic fibrosis (CF), where its portfolio of small-molecule CFTR modulators transformed standards of care for many people with the disease. The company operates research and development, manufacturing and commercial organizations and serves patients and healthcare systems in multiple international markets.

Vertex’s marketed products center on CFTR modulators that target the underlying cause of cystic fibrosis rather than just treating symptoms.